Skip to main navigation
Skip to search
Skip to main content
WashU Medicine Research Profiles Home
Help & FAQ
Home
Profiles
Departments, Divisions and Centers
Research output
Search by expertise, name or affiliation
Are changes in US practices for androgen deprivation therapy financially motivated?
Matthew D. Katz
, Gerald L. Andriole
Department of Surgery
Institute of Clinical and Translational Sciences (ICTS)
Siteman Cancer Center
Division of Urologic Surgery
Research output
:
Contribution to journal
›
Short survey
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Are changes in US practices for androgen deprivation therapy financially motivated?'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Luteinizing Hormone
100%
Androgen Deprivation Therapy
100%
Surgical Castration
75%
Reimbursement
50%
Orchiectomy
25%
Practice Patterns
25%
Treatment Decisions
25%
Patients with Prostate Cancer
25%
Financial Incentives
25%
Medicaid Patients
25%
Medicare Modernization Act
25%
Nursing and Health Professions
Androgen Deprivation Therapy
100%
Gonadorelin Agonist
75%
Medicare
50%
Reimbursement
50%
Prostate Cancer
25%
Orchiectomy
25%
Gonadorelin Derivative
25%
Veterinary Science and Veterinary Medicine
Androgen
100%
Gonadotropin-Releasing Hormone Agonist
75%
Gonadotropin-Releasing Hormone Analogue
25%
Prostate Cancer
25%
Orchiectomy
25%
Neuroscience
Androgen
100%
Gonadotropin-Releasing Hormone Agonist
75%
Gonadotropin-Releasing Hormone Analogue
25%
Psychology
Androgen
100%
Medicare
25%
Medicare Modernization Act
25%
Prostate Cancer
25%